NuVasive Inc. (NUVA) Drops 6.46% on February 15

Equities Staff |

NuVasive Inc. (NUVA) was one of the Russell 2000's biggest losers for Monday February 15 as the stock slid 6.46% to $39.12, a loss of $-2.7 per share. Starting at an opening price of $48.50 a share, the stock traded between $36.81 and $48.50 over the course of the trading day. Volume was 3.14 million shares over 23,382 trades, against an average daily volume of 593,926 shares and a total float of 49.1 million.

The losses send NuVasive Inc. down to a market cap of $1.92 billion. In the last year, NuVasive Inc. has traded between $56.61 and $36.81, and its 50-day SMA is currently $49.17 and 200-day SMA is $50.03.

The stock has a P/E Ratio of 34.9.

NuVasive Inc is a medical device company. The Company develops minimally-disruptive surgical products and procedurally-integrated solutions for the spine. Its currently-marketed product portfolio is focused on applications for spine fusion surgery.

NuVasive Inc. is based out of San Diego, CA and has some 1,500 employees. Its CEO is Gregory T. Lucier.

For a complete fundamental analysis analysis of NuVasive Inc., check out’s Stock Valuation Analysis report for NUVA. To see the latest independent stock recommendations from’s analysts, visit our Research section.

The Russell 2000 is one of the leading indices tracking small-cap companies in the United States. It's maintained by Russell Investments, an industry leader in creating and maintaining indices, and consists of the smallest 2000 stocks from the broader Russell 3000 index.

Russell's indices differ from traditional indices like the Dow Jones Industrial Average (DJIA) or S&P 500, whose members are selected by committee, because they base membership entirely on an objective, rules based methodology. The 3,000 largest companies by market cap make up the Russell 3000, with the 2,000 smaller companies making up the Russell 2000. It's a simple approach that gives a broad, unbiased look at the small-cap market as a whole.

For more news on the financial markets, go to Also, learn more about our independent proprietary equity research reports and our robust do-it-yourself Stock Valuation Analysis reports in our Research section.

All data provided by QuoteMedia and was accurate as of 4:30PM ET.

DISCLOSURE: The views and opinions expressed in this article are those of the authors, and do not represent the views of Readers should not consider statements made by the author as formal recommendations and should consult their financial advisor before making any investment decisions. To read our full disclosure, please go to:


Emerging Growth

PixarBio Corp

PixarBio Corp is a specialty pharmaceutical/biotechnology company focused on pre-clinical and commercial development of novel neurological drug delivery systems for post-operative pain.

Private Markets

Cross Campus

With over 500 members and operating 80,000 square feet by summer 2016, Cross Campus is one of the country’s top ten shared, collaborative office or "coworking" operators in the US.…


Our mission is to be the best place for people who care about music to create and discover thoughtfully curated playlists. In essence, 8tracks is a platform for online mixtapes.